AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
GRUPOSURA.CL
ACCE-researched

Grupo Sura ordinary (GRUPOSURA.CL) fair value

Financial Services · Insurance - Diversified · BVC · Colombia
COP 70420.00+0.54%
Market cap COP 23.08TNext earnings 2026-11-13Updated Oct 24, 2026 · valuation updating
Our verdict
No fair value
We are missing the financial data our models need for this company. It will appear once the data arrives.
Not valued: there are no financial statements on file yet.
ACCE opinionGrupo Sura ordinary (GRUPOSURA.CL)
Fair value
Not available
ACCE price target
COP 75000
Rating
Not rated
Horizon
12 months
ACCE price target published on 20 Oct 2026, 02:20 CEST.
Price used: COP 70420 at the close on 23 Oct 2026, 23:00 CEST.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
88
out of 100
P/E
10.9x
forward 8.8x
1-year return
+59.0%
Dividend yield
2.64%

Grupo Sura ordinary in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Grupo Sura is a Colombian diversified insurer and financial group, writing life, health, auto, property and pension business across Colombia and its Latin American operations, and it earns most of its premium through the pension and savings side of the house as well as its general insurance book. The advantage here is scale in a concentrated market: a 22.1% operating margin and a 52.2% gross margin sit well above what a typical regional insurer produces, and the 11.0% ROE suggests the capital base is still large relative to earnings. Revenue growth of 18.1% is the most useful number in the data set, because it points to premium expansion rather than a reliance on investment income or a single product line. The stock trades at 10.7 times trailing earnings with no forward multiple available, which means the market is pricing the current earnings base rather than a consensus growth path, a gap that a deeper look should close before any view is formed. Worth checking: how much of the 18.1% growth is organic versus currency or acquisition driven, and whether the margin holds once the regional mix shifts. The score of 88 and absence of index membership tells you the quality screen is strong while the name remains outside the major benchmarks.

AI-assisted·How I use AIWritten Oct 20, 2026

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where GRUPOSURA.CL's valuation models land
Price
COP 70420.00
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Recent performance

1 week
-0.8%
1 month
+2.1%
3 months
+32.9%
6 months
+35.1%
YTD
+30.4%
1 year
+59.0%

Recommendation history, last 12 months

DateTypeNewPreviousPrice
20 Oct 2026, 02:20 CESTACCE price targetCOP 75000first publicationCOP 70000

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

This security trades in COP. Exchange-rate movements can increase or reduce the result in your own currency.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full GRUPOSURA.CL page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth88Value100Quality67Momentum97Total88
Valuation
Trailing P/E
10.9x
Forward P/E
8.8x
PEG
0.11
P/B
no data
EV / Revenue
no data
Book value/sh
no data
Enterprise value
no data
Profitability
ROE
11.0%
FCF yield
16.17%
ROIC
5.9%
Health and risk
Debt / equity
0.55
Dividend yield
2.64%
Beta
no data

Price

+56.5% · 1Y

Ask anything about GRUPOSURA.CL

Answered from Grupo Sura ordinary fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 67% of peers
low 3.8x10.9xhigh 45.2x
ROEbetter than 33% of peers
low 1%11%high 20%
Div yieldbetter than 50% of peers
low 0.0%2.6%high 5.9%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
GRUPOSURA.CL Grupo Sura ordinaryCOP 70420.00--10.9x11.0%6788
ICICIGI.NS ICICI Lombard General Insurance Company Limited₹1592.00--31.3x13.6%6857
PFGRUPSURA.CL Grupo Sura preferredCOP 59440.00--9.2x11.0%6788
BNT Brookfield Wealth Solutions Ltd. Class A Exchangeable Limited Voting Shares$37.95--45.2x1.1%3941
ACGLO Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F$18.07--3.8x19.9%8744
AEG Aegon Ltd. New York Registry Shares$8.10$1336% below11.7x11.1%5951
AGN.AS Aegon Ltd.€7.31€1134% below12.4x11.1%5954

Sector report card

Where GRUPOSURA.CL ranks against its sector peers on each metric.

Computing percentiles…